Matthew E Nielsen

List of Publications by Citations

Source: https://exaly.com/author-pdf/11100346/matthew-e-nielsen-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

82
papers
3,669
citations
h-index

87
ext. papers
4,336
ext. citations
4.6
avg, IF

60
g-index

5.08
L-index

#	Paper	IF	Citations
82	Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. <i>European Urology</i> , 2010 , 57, 196-201	10.2	378
81	Bladder cancer. Nature Reviews Disease Primers, 2017, 3, 17022	51.1	360
80	Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. <i>Genes and Cancer</i> , 2010 , 1, 152-163	2.9	230
79	Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1141-1150	27.4	183
78	ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. <i>European Urology</i> , 2014 , 66, 77-84	10.2	169
77	Robotic radical cystectomy for bladder cancer: surgical and pathological outcomes in 100 consecutive cases. <i>Journal of Urology</i> , 2010 , 183, 510-4	2.5	157
76	Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. <i>European Urology</i> , 2007 , 51, 699-706; discussion 706-8	10.2	125
75	Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. <i>Journal of Urology</i> , 2010 , 183, 68-75	2.5	120
74	Robotic-assisted laparoscopic intracorporeal urinary diversion. <i>European Urology</i> , 2010 , 57, 1013-21	10.2	115
73	Sarcopenia as a predictor of complications and survival following radical cystectomy. <i>Journal of Urology</i> , 2014 , 191, 1714-20	2.5	114
72	Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 763-72	7.4	113
71	Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. <i>Cancer</i> , 2012 , 118, 54-62	6.4	108
70	Geriatric assessment in surgical oncology: a systematic review. <i>Journal of Surgical Research</i> , 2015 , 193, 265-72	2.5	103
69	High anterior release of the levator fascia improves sexual function following open radical retropubic prostatectomy. <i>Journal of Urology</i> , 2008 , 180, 2557-64; discussion 2564	2.5	93
68	Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. <i>European Urology</i> , 2012 , 61, 258-68	10.2	78
67	Gender Differences in Compensation, Job Satisfaction and Other Practice Patterns in Urology. <i>Journal of Urology</i> , 2016 , 195, 450-5	2.5	66
66	Systematic detection and repair of subclinical inguinal hernias at radical retropubic prostatectomy. <i>Urology</i> , 2005 , 66, 1034-7	1.6	66

(2007-2010)

65	Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. <i>Cancer</i> , 2010 , 116, 5517-26	6.4	65	
64	Insight on pathogenesis of varicoceles: relationship of varicocele and body mass index. <i>Urology</i> , 2006 , 68, 392-6	1.6	65	
63	Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base. <i>BJU International</i> , 2014 , 114, 46-55	5.6	64	
62	Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer. <i>Urology</i> , 2007 , 70, 1168-72	1.6	56	
61	A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. <i>BJU International</i> , 2007 , 100, 1015-20	5.6	50	
60	Long-term oncologic outcome after laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma. <i>European Urology</i> , 2007 , 51, 1639-44	10.2	50	
59	Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion"nadir + 2"?. <i>Urology</i> , 2008 , 72, 389-93; discussion 394-5	1.6	44	
58	Projecting the Urology Workforce Over the Next 20 Years. <i>Urology</i> , 2016 , 98, 21-26	1.6	41	
57	Nutritional predictors of complications following radical cystectomy. <i>World Journal of Urology</i> , 2015 , 33, 1129-37	4	36	
56	Integrating Patient Preference into Treatment Decisions for Men with Prostate Cancer at the Point of Care. <i>Journal of Urology</i> , 2016 , 196, 1640-1644	2.5	33	
55	Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer. <i>Cancer</i> , 2016 , 122, 2012-20	6.4	31	
54	Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. <i>Journal of Urology</i> , 2006 , 176, 515-9	2.5	30	
53	Burden of Multiple Chronic Conditions among Patients with Urological Cancer. <i>Journal of Urology</i> , 2018 , 199, 543-550	2.5	30	
52	Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1663-9	2.8	29	
51	Functional Outcomes Following Radical Cystectomy in Women with Bladder Cancer: A Systematic Review. <i>European Urology Focus</i> , 2017 , 3, 136-143	5.1	29	
50	Surgical advances in bladder cancer: at what cost?. <i>Urologic Clinics of North America</i> , 2015 , 42, 235-52, ix	2.9	23	
49	Oncologic outcomes for lymph node-positive urothelial carcinoma patients treated with robot assisted radical cystectomy: with mean follow-up of 3.5 years. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1621-7	2.8	22	
48	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 515-23	6.1	22	

47	Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. <i>BJU International</i> , 2012 , 110, 967-72	5.6	20
46	Readability of American online patient education materials in urologic oncology: a need for simple communication. <i>Urology</i> , 2015 , 85, 351-6	1.6	20
45	Urinary markers in the detection of bladder cancer: whatß new?. <i>Current Opinion in Urology</i> , 2006 , 16, 350-5	2.8	18
44	Receipt of guideline-concordant treatment in elderly prostate cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 332-8	4	17
43	Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit. <i>World Journal of Urology</i> , 2016 , 34, 3-11	4	16
42	Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. <i>World Journal of Urology</i> , 2006 , 24, 499-508	4	16
41	Epidemiology of Prostate and Testicular Cancer. Seminars in Interventional Radiology, 2016, 33, 182-5	1.6	15
40	Metabolic syndrome as a predictor for postoperative complications after urologic surgery. <i>Urology</i> , 2014 , 83, 1051-9	1.6	15
39	Lifestyle and nutritional modifiable factors in the prevention and treatment of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 380-386	2.8	15
38	Contemporary survival trends in penile cancer: Results from the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 674.e1-674.e9	2.8	14
37	The Expanding Role of Advanced Practice Providers in Urologic Procedural Care. <i>Urology</i> , 2017 , 106, 70-75	1.6	14
36	Extent of pelvic lymph node dissection during radical cystectomy: is bigger better?. <i>Reviews in Urology</i> , 2014 , 16, 159-66	1	13
35	Venous thromboembolism and effect of comorbidity in bladder cancer: A danish nationwide cohort study of 13,809 patients diagnosed between 1995 and 2011. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 292.e1-8	2.8	13
34	Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1895-903	6.1	12
33	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 386.e1-6	2.8	11
32	Genomic investigation of etiologic heterogeneity: methodologic challenges. <i>BMC Medical Research Methodology</i> , 2014 , 14, 138	4.7	11
31	Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection. <i>Urology</i> , 2007 , 70, 1091-5	1.6	11
30	The relationship of travel distance with cystectomy access and outcomes. <i>Urologic Oncology:</i> Seminars and Original Investigations, 2018, 36, 308.e1-308.e9	2.8	10

29	Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019 , 123, 307-312	5.6	10
28	The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC. <i>Prostate</i> , 2017 , 77, 878-887	4.2	9
27	Pilot Study of [F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 378-386.e1	3.3	9
26	The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. <i>Cancer Causes and Control</i> , 2016 , 27, 1475	- 1 485	9
25	Economic impact of training and career decisions on urological surgery. <i>Journal of Urology</i> , 2014 , 191, 755-60	2.5	8
24	Comparison of surveillance strategies for low-risk bladder cancer patients. <i>Medical Decision Making</i> , 2013 , 33, 198-214	2.5	8
23	Prevention and management of complications following robot-assisted radical cystectomy: lessons learned after >250 consecutive cases. <i>World Journal of Urology</i> , 2013 , 31, 441-6	4	7
22	Comprehensive handbook for developing a bladder cancer cystectomy database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 812-26	2.8	6
21	Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment. <i>Journal of Oncology Practice</i> , 2016 , 12, e423-36	3.1	6
20	Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2096-2106	6.7	5
19	Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy DatabaseUNC GOLD. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 32.e	1 2 9 ⁸	5
18	Advanced Practice Providers in U.S. Urology: A National Survey of Demographics and Clinical Roles. <i>Urology Practice</i> , 2017 , 4, 418-424	0.8	4
17	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Gufin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 4599-4609	12.9	4
16	Perioperative Intravesical Chemotherapy for Patients WithNon-Muscle-invasive Bladder Cancer: Understanding the Extent of and Sources of Variation in Guideline-recommended Use. <i>Urology</i> , 2019 , 124, 107-112	1.6	4
15	Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 737.e17-737.e23	2.8	3
14	Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 77.e1-77.e8	2.8	3
13	Effect of comorbidity on risk of venous thromboembolism in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 466-72	2.8	2
12	The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. <i>Cancer Causes and Control</i> , 2018 , 29, 1143-1150	2.8	2

11	Use of Evidence-Based Prostate Cancer Imaging in a Nongovernmental Integrated Health Care System. <i>Journal of Oncology Practice</i> , 2017 , 13, e441-e450	3.1	1
10	Patient Reported vs Claims Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer. <i>Journal of Urology</i> , 2021 , 205, 434-440	2.5	1
9	Patient-reported Health Status, Comorbidity Burden, and Prostate Cancer Treatment. <i>Urology</i> , 2021 , 149, 103-109	1.6	0
8	Implementation of Postoperative Standard Opioid Prescribing Schedules Reduces Opioid Prescriptions Without Change in Patient-reported Pain Outcomes. <i>Urology</i> , 2021 , 148, 126-133	1.6	O
7	Geriatric conditions and treatment burden following diagnosis of non-muscle- invasive bladder cancer in older adults: A population-based analysis. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 1022-1030	3.6	0
6	Characteristics of Physicians and Other Providers Frequently Ordering Intravenous Pyelograms. Journal of the American College of Radiology, 2019 , 16, 1153-1157	3.5	
5	Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Chevilleß letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84. European Urology,	10.2	
4	2014 , 66, e92 Editorial Comment. <i>Journal of Urology</i> , 2020 , 203, 552	2.5	
3	Editorial Comment. <i>Journal of Urology</i> , 2019 , 202, 246	2.5	
2	Editorial Comment. <i>Journal of Urology</i> , 2019 , 202, 1042-1043	2.5	

Perioperative Care: The Radical Cystectomy Pathway **2014**, 127-136